Saturday 17 October 2026 Export NMTC’s income statement to Excel — free account

NeuroOne Medical Technologies Corporation

In the quarter to June 2026, revenue grew 16.3%, EPS fell 27.8% and free cash flow grew 26.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.96 0.08 −7.69%

Follow NMTC

Alert me

Market cap: $9.5M
P/E: 0.0×
Fwd P/E: −5.1×
Dividend yield: —
F-score: 6/9
Altman Z: −3.72
Beneish M: 0.13
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.74

Total sells 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	1	—	—
Sell	—	—	—	—	3	—	—	1	—	—	—	—

Insider Ownership 16.30%

Capital & Financial Ratios $m

Market Cap 9.47

Revenue 9.47

Net Income (7.45)

Free Cash Flow (7.16)

Net Debt (2.05)

Current Ratio 2.84

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.08)

P/S ratio 0.88

P/B ratio 2.21

Past 5Y EPS Growth —

This Y EPS Growth (32.10%)

Next Y EPS Growth 11.21%

Next Y revenue growth (12.96%)

Next 5Y EPS Growth 14.29%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.08%

10-year low 10-year high

P/B against its own 10 years 10.80%

10-year low 10-year high

EV/Sales against its own 10 years 0.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	1	7	2
Receivables	—	0	1	1
Inventory	2	3	2	2
Other	—	—	—	—
	7	5	10	6

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	2	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	44.41%	78.70%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	27.90%	(9.70%)

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	3	2	2	—	—
’25	6	1	2	3	12
’24	1	1	1	0	3
’23	2	0	1	1	3
’22	0	0	0	2	2
’21	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(3)	(1)	(1)	—	—
’25	0	0	(1)	(2)	(3)
’24	(4)	(2)	(2)	(3)	(11)
’23	(3)	(4)	(3)	(3)	(13)
’22	(3)	(3)	(3)	1	(8)
’21	(2)	(2)	(2)	(2)	(9)
’20	—	(2)	(1)	4	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(3)	(1)	(1)	—	—
’25	0	0	(2)	(2)	(3)
’24	(4)	(2)	(2)	(3)	(11)
’23	(4)	(4)	(3)	(3)	(13)
’22	(3)	(3)	(3)	1	(8)
’21	(2)	(2)	(2)	(2)	(9)
’20	—	(3)	(1)	4	(4)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.18)	(0.25)	(0.28)	—	—
’25	0.36	(0.42)	(0.18)	(0.24)	(0.54)
’24	(0.84)	(0.66)	(0.60)	(0.66)	(2.76)
’23	(0.66)	(1.26)	(1.20)	(0.78)	(3.90)
’22	(1.08)	(1.14)	(1.02)	(0.54)	(3.78)
’21	(1.53)	(1.28)	(1.50)	(1.32)	(5.58)
’20	—	(1.74)	(7.96)	(0.08)	(15.11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	9.90	9.90	54.00	21.78	14.94	11.22	3.06	5.10	3.31	2.37	Analyst estimates 2026–2028 Powerpack
	High	9.90	76.50	180.00	178.02	46.80	81.00	19.08	13.08	10.07	8.34
People
People	Employees	—	—	—	—	—	11	15	16	17	18
	Revenue/emp, $m	—	—	—	—	0.00	0.02	0.14	0.21	0.20	0.67
Income, $m
Income, $m	Revenue	—	—	—	—	2	0	2	3	3	12
	Gross margin, %	0.00	0.00	0.00	0.00	100.00	(13.54)	88.59	56.10	31.27	67.30
	EBT	0	(5)	(7)	(7)	(14)	(10)	(10)	(12)	(12)	(4)
	EBT margin, %	0.00	0.00	0.00	0.00	(707.99)	(4,093.91)	(471.68)	(348.03)	(356.74)	(29.80)
	Net income	0	0	(7)	(7)	(14)	(10)	(10)	(12)	(12)	(4)
	Depreciation	0	0	—	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	2.13	0.14	0.79	1.13	0.77	1.81
	Earnings	(0.16)	(2.31)	(2.43)	(1.72)	(15.11)	(5.58)	(3.78)	(3.90)	(2.76)	(0.54)
	Cash flow	(0.07)	(0.96)	0.00	(1.37)	(3.79)	(4.82)	(2.82)	(4.27)	(2.47)	(0.42)
	Capex	0.00	0.00	0.00	0.00	(0.14)	(0.04)	(0.10)	(0.12)	(0.03)	(0.01)
	Free cash flow	(0.07)	(0.96)	0.00	(1.37)	(3.93)	(4.86)	(2.92)	(4.39)	(2.50)	(0.44)
	Book value	(0.11)	(2.29)	(1.57)	(0.31)	2.29	3.68	3.60	2.07	0.18	1.06
	Shares, m	2	2	3	4	1	2	3	3	4	7
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	173.99	12.76	4.95	7.67	2.95
	P/B	—	—	—	—	82.77	6.45	2.82	2.70	32.24	5.04
	EV/Sales	—	—	—	—	0.00	145.58	7.50	3.38	7.25	2.41
	EV/FCF	—	—	—	—	0.00	(4.11)	(2.04)	(0.87)	(2.25)	(9.97)
Cash, $m
Cash, $m	Operating cash flow	0	(2)	—	(5)	(3)	(9)	(8)	(13)	(11)	(3)
	Capex	—	0	—	0	0	0	0	0	0	0
	Free cash flow	0	(2)	—	(5)	(4)	(9)	(8)	(13)	(11)	(3)
Balance, $m
Balance, $m	Working capital	0	(4)	(4)	(1)	2	6	9	6	2	8
	Total debt	0	2	2	—	1	0	0	0	—	—
	Net debt	0	2	2	0	(4)	(7)	(11)	(5)	(1)	(7)
	Shareholders’ equity	0	(5)	(4)	(1)	2	7	10	6	1	7
Returns, %
Returns, %	ROA	(56.61)	(1,336.61)	(1,399.51)	(1,805.19)	(515.46)	(156.69)	(96.33)	(113.38)	(182.93)	(44.63)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(806.13)	0.00	(526.10)
	ROE	10.75	190.78	144.75	240.75	(3,292.35)	(230.81)	(123.77)	(149.61)	(348.39)	(91.34)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
SINT SINTX TECHNOLOGIES, INC.	$13.4M	— (loss-making)	— (loss-making)	+199.34% (above 0%: growing)	n/m	−38.60% (below 0%: shrinking)	61.50%	(638.94%)	Compare
PETV PetVivo Holdings, Inc.	$12.9M	— (loss-making)	— (loss-making)	+13.48% (above 0%: growing)	n/m	+40.13% (above 0%: growing)	66.14%	(476.54%)	Compare
BTCY Biotricity Inc.	$10.9M	— (loss-making)	— (loss-making)	+10.40% (above 0%: growing)	n/m	+235.83% (above 0%: growing)	82.55%	3.70%	Compare
CTSO Cytosorbents Corporation	$9.7M	— (loss-making)	— (loss-making)	+0.17% (above 0%: growing)	n/m	+64.90% (above 0%: growing)	73.18%	(27.39%)	Compare
NMTC NeuroOne Medical Technologies Corporation	$9.5M	— (loss-making)	— (loss-making)	+16.33% (above 0%: growing)	n/m	+26.91% (above 0%: growing)	59.94%	(122.87%)
BMRA Biomerica, Inc.	$8.6M	— (loss-making)	11.4×	+16.96% (above 0%: growing)	n/m	−35.05% (below 0%: shrinking)	(7.88%)	(174.77%)	Compare
AEMD Aethlon Medical, Inc.	$8.5M	— (loss-making)	— (loss-making)	+335.00% (above 0%: growing)	n/m	−11.13% (below 0%: shrinking)	0.00%	0.00%	Compare
TNON Tenon Medical, Inc.	$7.8M	— (loss-making)	— (loss-making)	+126.77% (above 0%: growing)	n/m	−21.78% (below 0%: shrinking)	63.64%	(262.24%)	Compare
Median of peers	$10.3M	—	—	+16.96%	—	+14.50%	62.57%	(101.08%)

All 149 Medical Devices stocks →

NeuroOne Medical Technologies Corporation (NMTC) key facts

NeuroOne Medical Technologies Corporation (NMTC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NMTC traded at $0.96, a market capitalization of $9.5 million.
Return on equity was −91.3% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −3.72 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.